Judge: Amgen will not have to put drug prices in TV ads
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Atara Biotherapeutics reports $58 million net loss
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →SerImmune gets $8 million in financing from Illumina Ventures
Santa Barbara immunotherapy and diagnostic company SerImmune received $8 million in financing from San Francisco-based Illumina Ventures to expand its immune mapping platform and database. Illumina invests primarily in early-stage companies researching genomics, life science and health care. A subsidiary of pharmaceutical giant Merck also participated in the financing round, alongside other undisclosed investors. Mapping Read More →
Read More →Agilent cancer treatment approved in Europe
Agilent Technologies, with offices in Carpinteria, announced a product designed to identify previously untreated non-small cell lung cancer patients with a tumor proportion score of 50 percent or more was approved for use in Europe in conjunction with Merck’s Keytruda therapy. Before using the product – called PD-L1 IHC 22C3 pharmDx and developed by Agilent Read More →
Read More →Amgen spends big to defeat Proposition 61
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen seeks European OK of biosimilar drug, partners with Merck on studies
Amgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
